ESLA vs. LYEL, ALEC, IPHA, GLSI, MGNX, GNLX, CKPT, CRGX, VXRT, and ADAP
Should you be buying Estrella Immunopharma stock or one of its competitors? The main competitors of Estrella Immunopharma include Lyell Immunopharma (LYEL), Alector (ALEC), Innate Pharma (IPHA), Greenwich LifeSciences (GLSI), MacroGenics (MGNX), Genelux (GNLX), Checkpoint Therapeutics (CKPT), CARGO Therapeutics (CRGX), Vaxart (VXRT), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry.
Estrella Immunopharma vs.
Lyell Immunopharma (NASDAQ:LYEL) and Estrella Immunopharma (NASDAQ:ESLA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, community ranking, risk, profitability, valuation and earnings.
Lyell Immunopharma has a beta of -0.35, meaning that its share price is 135% less volatile than the S&P 500. Comparatively, Estrella Immunopharma has a beta of 0.41, meaning that its share price is 59% less volatile than the S&P 500.
Lyell Immunopharma currently has a consensus price target of $1.00, suggesting a potential upside of 42.71%. Estrella Immunopharma has a consensus price target of $16.00, suggesting a potential upside of 981.08%. Given Estrella Immunopharma's stronger consensus rating and higher possible upside, analysts clearly believe Estrella Immunopharma is more favorable than Lyell Immunopharma.
In the previous week, Estrella Immunopharma had 4 more articles in the media than Lyell Immunopharma. MarketBeat recorded 6 mentions for Estrella Immunopharma and 2 mentions for Lyell Immunopharma. Estrella Immunopharma's average media sentiment score of 0.47 beat Lyell Immunopharma's score of 0.00 indicating that Estrella Immunopharma is being referred to more favorably in the news media.
Estrella Immunopharma has lower revenue, but higher earnings than Lyell Immunopharma. Estrella Immunopharma is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 0.4% of Estrella Immunopharma shares are held by institutional investors. 25.1% of Lyell Immunopharma shares are held by insiders. Comparatively, 55.1% of Estrella Immunopharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Estrella Immunopharma has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -323,792.09%. Lyell Immunopharma's return on equity of -34.64% beat Estrella Immunopharma's return on equity.
Lyell Immunopharma received 13 more outperform votes than Estrella Immunopharma when rated by MarketBeat users. However, 100.00% of users gave Estrella Immunopharma an outperform vote while only 48.28% of users gave Lyell Immunopharma an outperform vote.
Summary
Estrella Immunopharma beats Lyell Immunopharma on 11 of the 17 factors compared between the two stocks.
Get Estrella Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for ESLA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Estrella Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:ESLA) was last updated on 2/22/2025 by MarketBeat.com Staff
Free ESLA Stock Alerts